AHL Partners’s Nektar Therapeutics NKTR Stock Holding History

AHL Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-705	Closed	-$254K	–	1329
2017 Q3	$254K	Buy	+705	New	+$221K	﹤0.01%	1176
2015 Q3	–	Sell	-5,037	Closed	-$945K	–	775
2015 Q2	$945K	Buy	+5,037	New	+$867K	0.04%	558

Other funds holding NKTR

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

AHL Partners's NKTR Position: Q4 2017 in Review

AHL Partners sold out of Nektar Therapeutics (NKTR) in Q4 2017, closing a stake of 705 shares — an estimated $254K sold.

AHL Partners first reported a position in NKTR in Q2 2015 and held it in 2 quarters. The position peaked at $945K in Q2 2015. 265 funds tracked by Wall St. Rank hold NKTR as of Q4 2017.

AHL Partners reported no remaining Nektar Therapeutics position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 705 Nektar Therapeutics shares in Q4 2017, an estimated $254K.
AHL Partners first reported a position in Nektar Therapeutics in Q2 2015 and held it in 2 quarters.
AHL Partners's Nektar Therapeutics position peaked at $945K in Q2 2015.
265 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.